📸 Resilient Trader: The Imaging Boom Trade on RadNet (RDNT)

In partnership with

Resilient Trader is where smart traders come for vetted ideas.

Every week, we cut through the noise and surface opportunities that institutions are already eyeing, but with strategies tailored for retail traders.

Today’s setup? A healthcare powerhouse that’s firing on all cylinders, with multiple growth engines just kicking into high gear.

The Smartest Free Crypto Event You’ll Join This Year

Curious about crypto but still feeling stuck scrolling endless threads? People who get in early aren’t just lucky—they understand the why, when, and how of crypto.

Join our free 3‑day virtual summit and meet the crypto experts who can help you build out your portfolio. You’ll walk away with smart, actionable insights from analysts, developers, and seasoned crypto investors who’ve created fortunes using smart strategies and deep research.

No hype. No FOMO. Just the clear steps you need to move from intrigued to informed about crypto.

Secure your free pass now.

🔍 Trade Thesis: RadNet Is at the Center of a Medical Imaging Supercycle

RadNet (RDNT) isn’t just another healthcare stock - it’s the largest outpatient imaging network in the U.S., and it’s perfectly positioned to benefit from a massive multi-year growth cycle.

Here’s what’s driving the upside:

💥 PET/CT Is Exploding: Demand for high-margin PET/CT scans is surging, driven by new blockbuster drugs for Alzheimer’s and prostate cancer that require imaging for diagnosis and monitoring. PET/CT volumes have more than doubled in three years and are still growing 20%+ annually.

🏥 The Outpatient Shift: Patients and payors are migrating from expensive hospitals to cheaper, faster outpatient imaging centers, and RadNet is the market leader.

🤖 AI-Powered Efficiency: RadNet’s in-house AI (DeepHealth) is already improving radiologist productivity, enabling more volume and better throughput - a hidden growth driver even before future AI reimbursements kick in.

📈 Improving Fundamentals: Productivity and staffing are improving, setting the stage for a string of earnings beats heading into 2026.

📊 The Fundamentals Are Accelerating

From their blockbuster Q3 2025 report:

💰 Revenue: $522.9M (+13.4% YoY)

📈 Adjusted EBITDA: $84.9M (+15.2%) with margin expansion

🚀 PET/CT Volume: +21.1%

💪 Advanced Imaging Mix: 28.2% of total, up 153 bps

💵 Balance Sheet: Strong at ~1.0x Net Debt/EBITDA - plenty of flexibility for growth

📐 Valuation: Premium That’s Earned

RDNT trades at a premium, but it’s justified:

🏆 Market Leader: 347 centers - nearly 3x its closest competitor, giving it scale and pricing power.

📊 Analyst Ratings: 7/7 analysts rate it a Buy, with an average price target of $91.71 and a high target near $98.

🧭 Technicals: Coiling for the Next Leg Up

✅ Strong Uptrend: In a clear long-term trend from its $45 low.

✅ Consolidating: Holding steady around $78 after earnings - building a solid base.

✅ Support: Key support near $76.

🎯 Targets: $90 (initial), $98 (high).

💥 Trade of the Week: Buy the Stock, Juice It with Calls

This is a buy-and-hold setup for the next 12-18 months with optional leverage through calls.

🟢 Stock Trade

• Buy RDNT at $78.75

🛡️ Options Strategy

• Buy the June 18, 2026 $90 Call for $8.60

  • Strike: $90

  • Expiration: June 18, 2026

  • Premium: $860 per contract

Risk-Reward:

• Max Risk: $8.60 (premium paid)

• Max Reward: Unlimited

• Breakeven: $98.60

• The Setup: RDNT needs to trade above $98.60 by expiration - right in line with analyst highs.

🛑 Risk Management

Watch for:

• Potential staffing shortages returning

• Slower drug adoption curves

• Imaging reimbursement pressure

Always size positions accordingly and trade with a plan.

🚀 Catalysts on the Horizon

1. Earnings Beats: Easy comps ahead make upside surprises likely.

2. Guidance Hikes: Management already raised guidance twice this year.

3. Alzheimer’s Drug Adoption: PET/CT scan demand accelerates as Leqembi and Kisunla roll out.

4. AI Announcements: Any update on their DeepHealth AI platform could re-rate the stock.

🧠 Final Thoughts

RadNet is a rare combination of scale, innovation, and secular tailwinds. Between the outpatient shift, the PET/CT boom, and AI-driven efficiency gains, this company is positioned to dominate for years.

✅ Buy $RDNT ( ▲ 1.69% )  at $78.75 or better
💸 Buy the June 18, 2026 $90 Call for $8.60

We’ll be holding this one for the trend higher into mid 2026.

Want more trade ideas like this plus weekly options plays?

👉 Join the Paid Resilient Trader Newsletter for deeper strategies and market breakdowns.

Our paid newsletter gives you:

• Weekly stock + options trade ideas

  • Market commentary and macro insights

    • Easy-to-follow setups with defined risk

Stay Liquid, my friends.
- The Resilient Trader

Did you know you can get this delivered to your inbox weekly?